A better crystal ball to predict lung-cancer survival?

[1]  David E. Misek,et al.  Gene-expression profiles predict survival of patients with lung adenocarcinoma , 2002, Nature Medicine.

[2]  G. Byrnes,et al.  Surgery for early stage non-small cell lung cancer. , 2004, The Cochrane database of systematic reviews.

[3]  Ciro Casanova,et al.  The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. , 2004, The New England journal of medicine.

[4]  Kevin Carroll,et al.  Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer) , 2005, The Lancet.

[5]  Renato Martins,et al.  Erlotinib in previously treated non-small-cell lung cancer. , 2005, The New England journal of medicine.

[6]  M. Tsao,et al.  Unraveling the mystery of prognostic and predictive factors in epidermal growth factor receptor therapy. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  J. Ferlay,et al.  Global Cancer Statistics, 2002 , 2005, CA: a cancer journal for clinicians.

[8]  B. Asselain,et al.  4-year mortality in patients with non-small-cell lung cancer: development and validation of a prognostic index. , 2006, The Lancet. Oncology.

[9]  Anthony J Alberg,et al.  Epidemiology of lung cancer: looking to the future. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Xin Li,et al.  TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  G. Byrnes,et al.  Surgery for local and locally advanced non-small cell lung cancer , 2005 .